Linical CoTSE:2183 +2.91%44 PS Ratio is 0.55 as of Jul. 11, 2026, which is 67% below its 10-year median of 1.65. GuruFocus rates TSE:2183 with a GF Score™ of 44/100 and a GF Value™ of 円316.17 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Linical Co ranks better than 95.91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Linical Co's share price is 円212.00.
Linical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円383.68. Hence, Linical Co's PS Ratio for today is 0.55.
Good Sign:
Linical Co Ltd stock PS Ratio (=0.56) is close to 10-year low of 0.52.
The historical rank and industry rank for Linical Co's PS Ratio or its related term are showing as below:
TSE:2183'
s PS Ratio Range Over the Past 10 Years
Min: 0.52 Med: 1.65 Max: 6.3
Current: 0.55
During the past 13 years, Linical Co's highest PS Ratio was 6.30. The lowest was 0.52. And the median was 1.65.
TSE:2183's PS Ratio is ranked better than 95.91% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs TSE:2183: 0.55
Linical Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Linical Co was -17.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -11.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.50% per year.
During the past 13 years, Linical Co's highest 3-Year average Revenue per Share Growth Rate was 31.00% per year. The lowest was -94.50% per year. And the median was 11.90% per year.
Back to Basics: PS Ratio
Linical Co (TSE:2183) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Linical Co PS Ratio Related Terms
Linical Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Linical Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Linical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Linical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Linical Co's Share Price of today is 円212.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Linical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円383.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Linical Co (TSE:2183) has a PS Ratio of 0.55 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Linical Co and its competitors. This is 67% below median its historical median of 1.65. Over the past decade, Linical Co's PS Ratio has ranged from 0.52 to 6.30. According to the industry distribution chart, Linical Co ranks #38 out of 930 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Linical Co's PS Ratio too high?
Linical Co's current PS Ratio of 0.55 is 67% below median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 6.30. The Biotechnology industry median PS Ratio is 9.52. Linical Co's value of 0.55 is 94.2% below this industry median. Based on the distribution chart, Linical Co ranks #38 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Linical Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #38 out of 930 companies for PS Ratio. This places Linical Co in the top 4% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.52. Linical Co's value of 0.55 is 94.2% below this benchmark. Historically, Linical Co's own PS Ratio has ranged from 0.52 to 6.30 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 9.52, Linical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Linical Co's current PS Ratio of 0.55 is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Linical Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Linical Co's current PS Ratio is 0.55, which is 67% below median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円316.17, compared to a current price of 円212.00 — trading 32.9% below its estimated fair value. The current PS Ratio is 0.55, which is 67% below median its 10-year median of 1.65 and 94.2% below the Biotechnology industry median of 9.52. Linical Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Linical Co (TSE:2183), the current PS Ratio is 0.55 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円212.00 is trading 32.9% below its estimated GF Value™ of 円316.17.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
PS Ratio: 0.55 (67% below median its 10-year median of 1.65)
GF Value™: 円316.17 vs. price of 円212.00 (32.9% below fair value)
Industry Position: 94.2% below the Biotechnology median (#38 of 930)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
